drugset / Trial / NCT02593162
A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
RandomizedParallel-groupDouble-blindTreatment
Summary
Phase 2a study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 in combination with Ribavirin for a 12-week treatment duration in treatment-naïve participants with genotype 4 hepatitis C virus (HCV) infection.
Timeline
- Start
- 2015-10
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Faldaprevir | Small molecule | — | — |
| Subject | TD-6450 | Unknown | — | — |
| Background | Ribavirin | Small molecule | — | — |